Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
- First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesized
- REC-1245 is a potent and selective RBM39 degrader with a potential first-in-class profile in Solid tumors and Lymphoma
- >100,000 patients in the US and EU5 initially addressable
- 这是第一个通过端到端使用操作系统来识别新靶标和新化学物质的项目，该项目在目标识别到新药临床试验的研究在18个月内完成，合成了约200种化合物。
- REC-1245是一种有效且选择性强的RBM39降解剂，在实体肿瘤和淋巴瘤中可能具有首创的潜力。
- 针对美国和欧洲五国的超过100,000名患者最初可用。
SALT LAKE CITY, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma.
盐湖城，2024年12月03日（全球新闻通讯社）-- Recursion（纳斯达克:RXRX），一家领先的临床阶段科技生物公司，致力于解码生物学以彻底改善生活，今天宣布首位患者已在其REC-1245的1/2期临床试验中接受剂量治疗，该药物是一种用于治疗富含生物标志物的实体肿瘤和淋巴瘤的新化合物。
Recursion identified the novel regulatory role of RBM39 on CDK12 function using its AI-powered maps of biology. Recursion believes the modulation of RBM39 may be associated with a therapeutic effect in certain biomarker-enriched solid tumors and lymphoma. Preclinical data support that RBM39 degradation induces splicing defects which downregulate DNA Damage Response (DDR) networks and cell cycle checkpoints.
Recursion利用其人工智能驱动的生物学图谱，识别了RBM39在CDK12功能中的新调节作用。Recursion认为，RBM39的调节可能与某些生物标志物富集的实体肿瘤和淋巴瘤的治疗效果相关。临床前数据支持RBM39降解诱导剪接缺陷，进而下调DNA损伤反应（DDR）网络和细胞周期检查点。
译文内容由第三方软件翻译。
